Predictors of switching antipsychotic medications in the treatment of schizophrenia by Nyhuis, Allen W et al.
RESEARCH ARTICLE Open Access
Predictors of switching antipsychotic medications
in the treatment of schizophrenia
Allen W Nyhuis, Douglas E Faries, Haya Ascher-Svanum
*, Virginia L Stauffer, Bruce J Kinon
Abstract
Background: To identify patient characteristics and early changes in patients’ clinical status that best predict
subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.
Methods: This post-hoc analysis used data from a one-year randomized, open-label, multisite study of
antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when
clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard
psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics,
comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as
change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox
proportional hazards modeling was used to identify the best predictors of switching from the initially assigned
antipsychotic medication.
Results: About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year
study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior
year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by
the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and
Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.
Conclusions: Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and
can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive
symptoms and of akathisia following two weeks of treatment were among the more robust predictors of
subsequent switching of antipsychotics.
Background
Antipsychotic medications are mainstays in the clinical
management of schizophrenia. Although generally effec-
tive in ameliorating core manifestations of the disease,
some patients experience only suboptimal responses or
are intolerant of the medication. This may include insuf-
ficient improvement or even worsening of symptoms, as
well as a variety of treatment-related adverse events
[1,2]. Under such clinical circumstances, a change (i.e.,
switch) in the antipsychotic medication regimen is war-
ranted, representing a rational rescue treatment option
in the hope that the switch will result in better treat-
ment outcomes for the patient [3-10].
Reasons for antipsychotic switching or discontinuation
are varied [2,11]; however, data from naturalistic clinical
settings on the frequency of antipsychotic switching, as
well as the timing and predictors of such medication
changes, are limited. Previous studies evaluating predic-
tors of switching [12,13] assessed a relatively narrow
range of variables and did so for patients who may not be
representative of those treated in usual outpatient care
settings. Furthermore, previous research assessed predic-
tors of medication switching at discrete time points
[12,13], thus providing a time-limited context for this
dynamic treatment practice. For example, the study by
Weinmann and colleagues [13] evaluated switching from
first-generation to second-generation antipsychotics
among inpatients with schizophrenia. However, hospitali-
zations are often triggered by poor treatment responses
or nonadherence with the previous antipsychotic regimen
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(switches). Furthermore, inpatient data are not repre-
sentative of outpatient clinical practice settings.
Another study, by Sernyak and colleagues [12], used
an administrative claims database to identify predictors
of medication switching among patients with schizo-
phrenia treated at the Veterans Health Administration.
Independent variables included information about ser-
vice utilization, sociodemographic, and a few clinical
variables. The study concluded that high levels of out-
patient and inpatient service use were the most power-
ful predictors of switching, while sociodemographic,
institutional, diagnostic, and functional measures were
also predictive in some cases.
The purpose of our study was to expand current
research and identify individual patient characteristics
that best predict switching of antipsychotic medications
among predominately outpatients treated for schizo-
phrenia and related disorders. This study is focused on
patients who switch antipsychotic medication (switch-
ers), the ones who constitute the pool of patients who
remain engaged in treatment, for whom the clinicians
have to consider different treatment choices to replace
the current therapy. Unlike patients who drop out of
treatment (discontinuers), the switchers show interest in
further treatment and are available for initiation of alter-
native treatment options. Our previous research [14] has
suggested that although treatment discontinuation for
any cause (switch or discontinuation) is an important
proxy measure of a medication’s effectiveness, the differ-
ences between antipsychotic medications on this proxy
measure may be primarily driven by switching of the
medication (when switching is a study option) rather
than discontinuation. Our prior research [15] has also
helped to show that in the treatment of patients with
schizophrenia, switching antipsychotics may be a mean-
ingful marker of treatment failure, considering its signif-
icant association with more frequent and more rapid
use of acute care services (hospitalization and crisis ser-
vices) compared with persons remaining on their initial
treatment.
Therefore, to identify individual patient characteristics
that best predict switching of antipsychotic medications
in the treatment of schizophrenia, we conducted a post-
hoc analysis of a one-year randomized, open-label,
multisite cost-effectiveness study of antipsychotic medi-
cations in the treatment of schizophrenia in the United
States. Consistent with the parent study protocol,
switching of the initially randomized antipsychotic was
permitted if clinically warranted [16-18]. The objectives
o ft h ec u r r e n ts t u d yw e r et oa s s e s st h ef r e q u e n c yo f
antipsychotic switching, the time to switching, and the
patient and treatment characteristics that best predict
subsequent switching of antipsychotics over a one-year
period. We used numerous independent variables to
reflect baseline patient sociodemographic and clinical
characteristics, as well as early clinical changes observed
within the first two weeks of antipsychotic therapy.
Methods
Data source
We used data from a Lilly-sponsored, randomized,
open-label, one-year, multicenter, cost-effectiveness
study of antipsychotics in the treatment of schizophrenia
(HGGD). This study compared the cost-effectiveness of
initial treatment with olanzapine versus a “fail-first” on
typical antipsychotics (then olanzapine if indicated) and
versus initial treatment with risperidone. The study was
conducted at 21 sites in 15 states from May 1998
through September 2002, and its primary findings have
been published [17]. Briefly, the study found that requir-
ing failure on less expensive antipsychotics before use of
olanzapine did not result in total cost savings, despite
significantly higher antipsychotic costs with olanzapine.
The study included patients who were deemed by
their physicians to warrant a change in their antipsycho-
tic medication, using broad eligibility criteria: patients
aged 18 years or older with a DSM-IV diagnosis of schi-
zophrenia, schizoaffective, or schizophreniform disorder,
provided they scored ≥18 on the Brief Psychiatric Rating
Scale (BPRS) [19]. No patient was excluded because of
comorbid substance use disorders or other psychiatric
or medical comorbidities, unless the condition was
severe. Almost all enrollees were outpatients (95%).
At study initiation, patients were randomized to one
of three open-label treatment groups: olanzapine (n =
229); risperidone (n = 221); or first-generation antipsy-
chotic of physician’s choice (n = 214). Patients remained
on their initially assigned medication for at least eight
weeks, after which, if clinically warranted per clinicians’
judgment, patients’ regimens could be changed to a dif-
ferent antipsychotic agent. Patients were assessed at
baseline and at five predetermined post-baseline visits (2
weeks; 2, 5, 8, and 12 months post-baseline), regardless
of the time of medication switch. The protocol and con-
sent procedures were approved by institutional review
boards, and after being provided with a complete
description of the study, signed consent forms were
obtained from patients prior to participation.
Assessments and predictor variables
A wide range of independent variables was evaluated in
patients who switched antipsychotic treatment com-
pared with their counterparts who completed the study
without a switch.
Baseline sociodemographic variables included age,
gender, race/ethnicity, educational attainment, marital
status, employment, and insurance status. Baseline
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life, functional status, safety and tolerability, hospitaliza-
tions and emergency services in the year prior to enroll-
ment, illness duration, use of antipsychotic and
switching of antipsychotics in the prior year, prior
adherence with antipsychotics defined as the medication
possession ratio (MPR, the proportion of days with any
antipsychotic during the one-year prior to enrollment),
pre-existing comorbid psychiatric and non-psychiatric
conditions (assessed at enrollment, including depression
and insomnia), total number of pre-existing comorbid
conditions of any type, past incarcerations, and past sui-
cide attempts.
To help identify predictor variables that emerge dur-
ing the early phase of treatment ("early on-treatment
variables”), a wide range of variables was measured at
baseline and again at two weeks post-baseline to com-
pute a two-week change score. These “on-treatment
variables” reflected measures of symptomatology, quality
of life, functional status, safety, and tolerability. Changes
occurring during the first two weeks of treatment were
used based on previous research showing that most
improvements are observed during the first two weeks
of treatment [20] and that early non-response to medi-
cation is a robust predictor of subsequent non-response
to the same antipsychotic medication [21-24].
Symptomatology was assessed using the Positive and
Negative Syndrome Scale (PANSS) [25] total score and
the five PANSS factor subscales [26]. Quality of life was
assessed using the 17 subscales (nine subjective, eight
objective) of the Lehman Quality of Life Interview [27].
Functional status was measured with the eight subscale
scores and two composite scores of the MOS 36-item
short form health survey (SF-36) [28]. Global assessment
of functioning (GAF) was also included [29].
Safety and tolerability (at baseline and again following
two weeks of treatment) was determined using clinician-
rated scales for akathisia [30] and extrapyramidal symp-
toms [31]. Baseline body weight and treatment-emergent
weight gain during the first two weeks of treatment
were assessed. The study did not include measures of
metabolic parameters (other than weight) or prolactin
levels.
Statistical analysis
Data from patients who discontinued their initially
assigned antipsychotic and were switched to another
antipsychotic within 14 days of medication discontinua-
tion (switchers) were compared with those who com-
pleted the one-year study on their randomized
medication (nonswitchers). Patients who discontinued
the study early (dropouts) without a switch prior to
study discontinuation were not included in the present
analysis. The switcher group was aggregated across the
three medication treatment groups, as was the non-
switcher group. This was done since the assessed rea-
sons for switching (i.e., patient request, lack of efficacy,
medication intolerability, other) did not significantly dif-
fer among the three treatment groups, although the
switching rate was significantly lower for patients rando-
mized to olanzapine (14%) compared to a typical anti-
psychotic (53%, p < .001) and to risperidone (31%, p <
.001) [17].
Chi-square, Fisher’s exact, Wilcoxon rank-sum, and
independent t tests were used to conduct univariate
comparisons of all potential predictor variables between
switchers and nonswitchers. The relationship between
each potential predictor variable and time to switching
was assessed univariately using Cox proportional
hazards regression. Time to switching was defined as
remaining in the study on the initially assigned medica-
tion without switching. If a patient’sr e g i m e nw a sn o t
switched over the one-year study period, the survival
time (time to switching) was censored either at study
completion or when the patient prematurely discontin-
ued the study.
Predictor variables identified from the above analyses
(with p < .05 from either the univariate survival analysis
or the comparisons between switcher and nonswitcher
groups) were used as initial variables in fitting a predic-
tive model using Cox proportional hazards, with the
outcome variable being time-to-switch. Using this initial
model as a starting point, the final predictor variables
were determined by utilizing a manual stepwise proce-
dure (with p < .05 as the criterion for variables to either
enter or stay in the model), using all of the potential
predictor variables (including variables not in the initial
model). Once the final predictors were determined, all
two-way interactions involving the final predictor vari-
ables were tested for inclusion in the final model. Signif-
icance was defined a priori at a two-tailed alpha ≤.05.
As a sensitivity analysis, the final predictive model was
refit on only the set of patients who did not continue
o nt h es a m et r e a t m e n ta tr a n d o m i z a t i o na st h e yw e r e
already taking pre-baseline. This was done to address
the possibility that continuing on the same treatment
might be predictive of earlier or later switching.
To illustrate the associations between each of the final
predictor variables and time to switching, a graph of the
Kaplan-Meier estimated survival distribution was pro-
duced in a univariate fashion separately for each predic-
tor variable.
Results
Of 664 patients enrolled in the parent study, 16 (2.4%)
either failed to or delayed taking their randomized med-
ication, leaving an analysis dataset of 648 patients (Fig-
ure 1). A total of 304 (46.9%) of the 648 patients
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medication (i.e., nonswitchers), whereas 191 (29.5%)
switched to a different antipsychotic (i.e., switchers).
The remaining 153 patients (23.6%) discontinued parti-
cipation in the study without switching to a new medi-
cation prior to dropout. These “early discontinuers” had
a mean age of 41.3, with 70% of them Male, 49% Cauca-
sian, 53% Single/Never Married, and their mean Total
PANSS score was 88.3. Only 14% of this group were
Employed, but 55% had a Substance Abuse diagnosis in
the past year, and 60% of them have been Incarcerated.
Among medication switchers, the reasons for the
switching were noted as patient decision (34.6%), lack of
medication efficacy (27.7%), adverse event (22.5%), and
other or unknown reasons (15.2%). Results of the uni-
variate analyses revealed several variables that were sig-
nificantly (p < .05) associated with switching: female
gender; no previous antipsychotic treatment in the year
before study initiation; no current or lifetime diagnosis
of substance use disorder; pre-existing insomnia; and
early (within two weeks post-baseline) worsening of
depressive symptoms per scores on the depression/anxi-
e t ys u b s c a l eo ft h eP A N S S( T a b l e1 ) .B a s e l i n eb o d y
weight and change in weight during the first two weeks
of treatment did not predict switching in this study.
Similarly, quality of life, functional variables, employ-
ment, insurance status, and adherence level in prior year
(per MPR) were not predictiveo fs w i t c h i n go re a r l i e r
switching.
According to the multivariate regression model, six
variables were found to significantly predict (p < .05)
antipsychotic switching: four baseline patient
characteristics and two early treatment variables (Table
2). The four baseline characteristics were female gender,
pre-existing depression, lack of antipsychotic medication
use in the year prior to the study, and lack of substance
use disorder. The two early treatment variables were
worsening of anxiety/depression symptoms (per PANSS
subscale score) and worsening of akathisia (per Barnes
Akathisia objective score) in the first two weeks of treat-
ment. According to the hazard ratios, women were
37.6% more likely to switch earlier than their male
counterparts, and patients with pre-existing depression
were 48.4% more likely to switch before similar patients
without pre-existing depression. Alternatively, partici-
pants less likely to switch medications included those
who were treated with any antipsychotic in the year
before the study (38.3% less likely) and those diagnosed
with substance use disorder (26.9% less likely).
There were two early treatment variables significantly
predictive of an increased likelihood of earlier switching,
one associated with medication efficacy and the other
with medication intolerability. These variables were an
increase (worsening) of the PANSS depression/anxiety
subscale score and an increase (worsening) of the Barnes
Akathisia objective score (Table 2) in the first two weeks
of treatment. According to the hazard ratios, for every 1-
point increase on the PANSS depression/anxiety subscale
score, patients had a 5.1% higher likelihood of switching
sooner than those without such changes in scores. A 2-
point increase in the PANSS depression/anxiety subscale
score was associated with a 10.5% higher likelihood of
switching earlier, whereas a 1-point decrease (improve-
ment) reduced the likelihood of an earlier switch by 4.9%.
Figure 1 Analytical Sample.
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Variable All
patients
(N = 648)
Switchers
(n = 191)
Completers
(n = 304)
p value
(switchers
vs.
completers)
1
pv a l u e
(univariate
survival
comparison)
2
Age, mean (SD), y 42.9 (12.1) 42.8 (12.5) 43.7 (11.8) 0.404 0.724
Female, n (%) 239 (37%) 87 (46%) 106 (35%) 0.018 0.013
Caucasian, n (%) 352 (54%) 107 (56%) 170 (56%) 0.998 0.890
Currently employed,
n (%)
122 (19%) 36 (19%) 64 (21%) 0.568 0.903
Illness duration, mean (SD), y 20.6 (12.2) 20.6 (12.6) 21.3 (12.1) 0.577 0.981
Hospitalized, previous year, mo
mean (SD)
0.51 (1.53) 0.40 (1.25) 0.49 (1.54) 0.450 0.343
Switch in previous year, n (%) 85 (13%) 23 (13%) 44 (15%) 0.588 0.650
Any antipsychotic previous year, n (%) 579 (89%) 165 (86%) 284 (93%) 0.011 0.095
Substance abuse diagnosis, n (%) 289 (45%) 70 (37%) 135 (44%) 0.111 0.038
Schizoaffective diagnosis, n (%) 280 (43%) 80 (42%) 130 (43%) 0.852 0.795
Ever attempted suicide, n (%) 235 (38%) 78 (43%) 99 (34%) 0.064 0.084
Ever incarcerated,
n (%)
284 (46%) 71 (38%) 127 (43%) 0.295 0.075
PANSS total score, mean (SD) 86.8 (20.0) 84.5 (18.8) 87.4 (21.1) 0.120 0.102
PANSS Davis, positive symptoms, mean (SD) 22.3 (6.3) 21.9 (5.8) 22.1 (6.6) 0.796 0.545
PANSS Davis, negative symptoms, mean (SD) 21.3 (7.0) 20.4 (6.8) 21.9 (7.3) 0.026 0.043
PANSS Davis, impulsivity/hostility, mean (SD) 8.9 (3.6) 8.9 (3.9) 8.9 (3.6) 0.990 0.675
PANSS Davis, disorganized thought, mean (SD) 21.2 (6.0) 20.7 (5.6) 21.6 (6.3) 0.096 0.085
PANSS Davis, anxiety/depression, mean (SD) 13.0 (4.2) 12.7 (4.0) 13.0 (4.3) 0.411 0.445
SF-36 Physical component score, mean (SD) -0.43 (1.04) -0.43 (1.05) -0.42 (1.01) 0.963 0.803
SF-36 Mental component score, mean (SD) -1.08 (1.33) -1.14 (1.33) -0.82 (1.28) 0.009 0.106
Barnes Akathisia 0.24 0.20 (0.53) 0.25 (0.62) 0.356 0.273
item #1, objective, mean (SD) (0.57)
Barnes Akathisia, total score, mean (SD) 0.99 (1.58) 0.96 (1.46) 0.95 (1.67) 0.954 0.813
GAF functioning, current score, mean (SD) 46.1 (12.9) 47.2 (13.4) 47.0 (13.2) 0.842 0.323
Antidepressant Drugs taken (%) 297 (46%) 85 (45%) 212 (46%) 0.667 0.340
Anti-Anxiety
Drugs taken (%)
187 (29%) 54 (28%) 133 (29%) 0.850 0.810
Antiparkinsonian
Drugs taken (%)
315 (49%) 93 (49%) 222 (49%) 1.000 0.453
Patient weight, mean (SD), kg 86.7 (20.7) 86.9 (21.2) 87.7 (20.4) 0.706 0.947
Body mass index, mean (SD) 29.7 (6.8) 30.4 (7.1) 29.8 (6.9) 0.426 0.229
Patient weight change from baseline to 2 weeks, mean (SD), kg +0.8 (2.8) +0.7 (3.2) +0.8 (2.4) 0.706 0.646
Pre-existing depression, n (%) 96 (15%) 36 (19%) 39 (13%) 0.073 0.056
Pre-existing insomnia, n (%) 66 (10%) 26 (14%) 24 (8%) 0.047 0.030
PANSS Davis anxiety/depression, change from baseline to 2 weeks,
mean (SD)
-1.42 (3.47) -1.19 (3.74) -1.88 (3.36) 0.041 0.093
Barnes Akathisia objective score, change from baseline to 2 weeks,
mean (SD)
-0.04 (0.59) +0.02
(0.62)
-0.05 (0.57) 0.193 0.058
Abbreviations: PANSS, positive and negative syndrome scale; SD, standard deviation; SF-36, Medical Outcomes Study 36-item short form health survey; GAF,
global assessment of functioning scale.
1Univariate descriptive statistic comparisons, using unpaired t-tests for numeric data (confirming with Wilcoxon rank-sum test, if non-normality was suspected) or
chi-square tests (or Fisher’s exact test, for small numbers) for categorical data.
2Univariate survival comparisons, using Cox proportional hazards models with only the one single variable.
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Akathisia objective score, there was a 34.5% increased
likelihood of switching earlier, whereas each 1-point drop
was associated with a 25.7% decreased likelihood of ear-
lier switching as compared with patients whose Barnes
Akathisia scores did not drop.
In order to assess how much each predictor has con-
tributed to the model, we determined how much the
likelihood ratio changed when each of the six predictor
variables was dropped from the model. This provided
the rank order from the most to the least significant
predictor (smaller number is better, as it indicates a
greater effect of dropping that predictor): worsening of
PANSS anxiety/depression score during the first two
weeks of treatment (likelihood ratio = 19.325); female
gender (likelihood ratio = 19.364); lack of antipsychotic
medication use in the prior year (likelihood ratio =
19.429); worsening of akathisia in the first two weeks of
treatment (likelihood ratio = 19.507); pre-existing
depression (likelihood ratio = 19.714); and lack of sub-
stance use disorder (likelihood ratio = 20.149). Although
Cox proportional hazards regression does not provide a
simple statistic (like R-square) to measure the percen-
tage of the total variance in switching explained by the
model, the relative “fit” of the model, as assessed by
comparing the model with versus without the six pre-
dictor variables, indicated a highly significant fit (likeli-
hood ratio = 23.836, p = .0006).
In the survival plots in Figures 2, 3, 4, three of the six
significant (p < .05) predictors of switching (or earlier
switching) are illustrated. The figures augment informa-
tion about the likelihood of switching with information
about the time to switching over the one-year study. Of
note, worsening in medication efficacy and tolerability
within the first two weeks of treatment is clearly signifi-
cantly associated with earlier switching (Figures 3 and 4).
Discussion
In this post-hoc analysis of a randomized, open-label
study conducted in naturalistic, predominately outpatient
settings, nearly one in three (29%) patients switched
before completing one year of therapy with the initially
assigned antipsychotic medication. Switching antipsycho-
tics was best predicted by six variables: four baseline and
two early on-treatment variables. These included, from
most to least statistically significant predictor: worsening
of PANSS anxiety/depression score during the first two
weeks of treatment, female gender, lack of antipsychotic
medication use in the prior year, worsening of akathisia
in the first two weeks of treatment, pre-existing depres-
sion, and lack of substance use disorder. These six vari-
ables were significantly predictive of both switching and
of an earlier time to switch. To our knowledge, this is the
first study to document patient-level risk factors for ear-
lier switching.
Current findings might help inform clinical decision-
making in usual practice. Effectively tailoring treatment
regimens to patients and optimizing early treatment
responses are pivotal challenges in psychiatry. For at
least four decades, researchers have sought predictors of
treatment outcomes after prescribing antipsychotic med-
ications, with a focus on baseline patient variables (i.e.,
“moderators”) and on-treatment variables (i.e., “media-
tors”) [32]. Findings that early worsening in depressive
and anxiety symptoms and in akathisia during the first
two weeks of treatment predicted switching or earlier
switching support the need for early monitoring of anti-
psychotic efficacy, tolerability, and safety to optimize
treatment outcomes.
Given the observed associations, medication switching
(as well as early medication discontinuation for any cause)
may constitute a proxy or surrogate marker of treatment
failure in many patients. This is important because treat-
ment failure often translates into relapse, which is one of
the costliest aspects of schizophrenia management in both
economic and human terms [6,33-35]. The sooner such
an adverse outcome can be predicted, the sooner treat-
ment can be modified to help avert it.
In addition to early-treatment predictors (mediators), a
number of baseline patient characteristics (moderators)
Table 2 Proportional Hazards Model of Predictor Variables
Variable Cox proportional
hazards model
parameter
p value Hazard ratio
(95% confidence
interval)
Female +0.3192 0.0335 1.376 (1.025-1.847)
Any antipsychotic in the previous year -0.4836 0.0262 0.617 (0.403-0.944)
Substance abuse diagnosis -0.3133 0.0457 0.731 (0.538-0.994)
Pre-existing depression condition +0.3948 0.0344 1.484 (1.029-2.139)
PANSS Davis anxiety/depression, change from baseline to 2 weeks +0.0498
(per 1-point increase)
0.0320 1.051 (1.004-1.100)
(per 1-point increase)
Barnes akathisia objective score, change from baseline to 2 weeks +0.2962
(per 1-point increase)
0.0398 1.345 (1.014-1.783)
(per 1-point increase)
Abbreviations: PANSS, positive and negative syndrome scale.
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Figure 3 PANSS Davis Anxiety/Depression Change From Baseline to 2 Weeks.
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lier switching. Patients who did not use antipsychotic
medications in the year preceding the study were more
likely to switch or require an earlier switch, likely reflect-
ing prior nonadherence with antipsychotic medications
in these chronically and moderately ill patients. Previous
research by our group demonstrated that patients with
schizophrenia who were enrolled in a large three-year
prospective observational, noninterventional study (US-
SCAP) and were nonadherent to antipsychotic medica-
tion regimens in the six months before enrollment were
over four times more likely to subsequently discontinue
such treatment for any cause [36].
In the present study, women with schizophrenia were
also significantly more likely than their male counter-
parts to switch medications or evidence an earlier medi-
cation switch. This finding, however, may reflect
ascertainment bias, in that women with schizophrenia
may, in general, use mental health services more fre-
quently than their male counterparts [37]. Increased ser-
vice use (e.g., physician visits) might in turn be
associated with a higher likelihood of detecting a subop-
timal treatment response or a treatment-emergent
adverse event culminating in medication switching [38].
We also found that patients diagnosed with a sub-
stance use disorder were less likely to switch antipsycho-
tic medications and less likely to switch earlier. This
predictor seemed, at first, somewhat at odds with pre-
vious research, especially with findings of a large,
prospective, observational study in which patients with
schizophrenia with concurrent substance abuse pro-
blems were more likely to discontinue antipsychotic
regimens for any cause [14]. However, all-cause medica-
tion discontinuation is composed of medication switch-
ing and study discontinuation, two components on
which patient subgroups seem to differ. The importance
of separating switchers from study discontinuers was
illustrated in a previous analysis of the current study
dataset (HGGD). In that post-hoc analysis [14], patients
with substance use were significantly more likely to dis-
continue their medication and to withdraw from the
study rather than switch medications. Furthermore, the
finding that patients with substance use disorders were
less likely to switch antipsychotic medications and less
likely to switch earlier might also represent the con-
founding by gender, because switchers were more likely
to be women and substance use is less prevalent among
women than men [37].
Arguably one of the most important findings of the
current study is that affective symptoms and, specifi-
cally, depressive and anxiety symptoms (pre-existing
depression and worsening of depression and anxiety
symptoms during the first two weeks of treatment),
appear to be robust predictors of subsequent switching
or earlier switching of medication. Current findings are
consistent with previous research demonstrating that
depressive symptoms are associated with a significantly
higher propensity to discontinue treatment for any
Figure 4 Barnes Akathisia Objective Score Change From Baseline to 2 Weeks.
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investigated this aspect in some detail, with a post-hoc
analysis of pooled data from four antipsychotic trials for
the treatment of schizophrenia (n = 1,627). That study
showed that patients with a 4-point improvement in
PANSS depression/anxiety subscore were significantly
less likely to discontinue treatment, and an early
response in depressive/anxiety symptoms was associated
with a 50% greater likelihood of study completion.
These, along with the current findings, emphasize the
prognostic value of affective symptoms, especially
depression and anxiety, in the treatment of patients with
schizophrenia.
The current findings also highlight the importance of
early worsening akathisia as a predictor of medication
switching. These results are consistent with prior
research showing that akathisia is bothersome and dis-
tressing to patients [42-44] and is associated with medi-
cation nonadherence [45,46].
It is of interest that no association was found between
medication switching and baseline body weight, BMI, or
treatment-emergent body weight in the first two weeks
of treatment. It is possible that health concerns about
treatment-emergent weight gain were not yet pro-
nounced during the study period (through 2002), thus
did not lead to medication switching by the clinicians. It
is also possible that clinicians have recognized the asso-
ciation between therapeutic response and greater treat-
ment-emergent weight gain [47-50] and opted, after
risk-to-benefit assessment, not to switch most of these
patients’ medications. These hypotheses are speculative,
as further research is needed to help clarify reasons for
medication continuation and reasons for medication dis-
continuation from the patients’ and clinicians’
perspectives.
The CATIE schizophrenia study [2,4,6,7] found that
individuals who had “continuation” (randomized to the
same antipsychotic they had received prior to study
entry) had significantly longer times to all-cause discon-
tinuation. Indeed, when this variable was tested in our
study, it was a significant predictor (p < .001) of switch-
ing. When, as a sensitivity analysis, the final predictive
model was re-fit to only the set of patients (n = 442)
who did not have continuation, the results showed
hazard ratios which were directionally consistent with
the original predictive model.
Study findings need to be evaluated in light of its lim-
itations. First is the study’s post-hoc nature, suggesting
the need for additional longitudinal research to confirm
the findings in an a priori manner. Second, patients
enrolled in this study were primarily chronically ill out-
patients with schizophrenia with about 20 years of ill-
ness duration, who agreed to participate in a
randomized study; therefore, our findings may not be
applicable to first-episode patients to inpatients, or to
patients treated in a usual care setting. In addition, this
study was conducted during a timeframe when second-
generation antipsychotics were fairly new to the market,
so it is not clear how changes in the standards of
treatment over time may have impacted the switching
decision-making process. Another limitation is the time-
to-event survival analysis: whether “censored” (discon-
tinued from the study) subjects would have soon
switched medication cannot be determined since they
were not followed up after dropping out of the study.
This limitation may help explain the finding that a lack
of substance use disorder was predictive of switching,
because substance users are prone to study discontinua-
tion rather than to switch medications [14,51]. Tradi-
tional survival analyses assume that censoring is
independent of the outcome event (in this case, switch-
ing), an assumption that is not likely to be fully satisfied.
Next, although a relatively wide range of potential pre-
dictors of switching was examined, the list was not
exhaustive. The study lacked data on changes in meta-
bolic parameters (besides body weight) and prolactin
levels, and these changes may lead some clinicians to
switch medications. Consequently, further research is
needed to incorporate such important safety measures
when assessing predictors of switching. In addition, the
most frequent reason for switching was “patient’sd e c i -
sion,” thus limiting the ability to discern what may have
triggered the switch for a substantial proportion of the
patients. Finally, but most importantly, this study
focused on switchers and not on patients who discontin-
ued the study early, although information about discon-
tinuers is also of interest and clinical importance.
Therefore, further research is needed to compare base-
line and early treatment characteristics of switchers and
discontinuers and assess whether predictors of switching
differ from predictors of medication discontinuation in
the treatment of patients with schizophrenia. Despite its
limitations, this study has a number of strengths. In
addition to conducting survival analyses to assess time
to switching, the study used liberal eligibility criteria and
was conducted in naturalistic settings, which may
enhance the ability to generalize the current findings to
the wider U.S. outpatient schizophrenia patient popula-
tion. Another strength of the present study is the broad
spectrum of patient-level variables examined as potential
predictors and the use of “early on-treatment” variables
to assess the predictive value of early changes in
patients’ status to reflect the medication’s early efficacy,
tolerability, and safety.
Conclusions
In conclusion, switching antipsychotic medications is
common in the outpatient management of schizophrenia
Nyhuis et al. BMC Psychiatry 2010, 10:75
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Page 9 of 11and can be considered a surrogate for treatment failure in
many patients. Early suboptimal treatment outcomes in
terms of efficacy (worsening of depressive/anxiety symp-
toms) and tolerability (worsening of akathisia) signifi-
cantly predict switching or an earlier time to switch.
Patient characteristics predictive of switching earlier
included female gender, a history of depression, and the
lack of recent use of antipsychotics. Further longitudinal
studies are needed to evaluate and replicate these
findings.
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